Company Overview and News

Why Hold Strategy is Apt for Accenture (ACN) Stock Right Now

2018-04-20 zacks
A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions.
Upvote Downvote

Accenture Rides on Cloud Strength & Buyouts, Competition Rife

2018-04-05 zacks
Accenture plc (ACN - Free Report) is witnessing strong demand for its services owing to solid performance across its insurance, banking and health care segments.
Upvote Downvote

Blog Coverage Accenture Acquires Communication Agency Kunstmaan; Also Selects UM as Strategic Media Buying and Planning Partner

2017-04-21 accesswire
LONDON, UK / ACCESSWIRE / April 21, 2017 / Active Wall St. blog coverage looks at the headline from Accenture PLC. (NYSE: ACN). Accenture announced the acquisition of Belgium based independent communication agency – Kunstmaan, on April 20, 2017. The acquisition will boost Accenture Interactive to expand and strengthen its presence in the Belgium market. The financial details of the deal were not disclosed.
Upvote Downvote

Accenture's Minor Sell-Off Is A Buying Opportunity

2017-03-27 seekingalpha
Accenture plc (NYSE:ACN), had a very busy month. This article will review its most recent earnings release, look at its recent corporate activity, and take a look at how the market reacted to all of this news to see if there is an opportunity to either initiate a position or to add to an existing position in Accenture.
Upvote Downvote

Blog Coverage Accenture Completes the Acquisition of OCTO Technology; Expands its Digital Solutions Portfolio

2017-03-22 accesswire
LONDON, UK / ACCESSWIRE / March 22, 2017 / Active Wall St. blog coverage looks at the headline from Accenture PLC (NYSE: ACN) as the Company announced on March 21, 2017, that it has completed the acquisition of OCTO Technology, a firm specializing in digital transformation services and software development. This statement is pursuant to the previously announced acquisition of the Company on September 15, 2016.
Upvote Downvote

Reboot to digital

2017-02-26 thehindubusinessline
IT’s on track, declare some. Not really, say others. Of late, opinion is divided on the strategy adopted by Indian IT companies. While one set of investors criticise them for keeping cash idle and losing the race to global peers, the other set is glad that they are not setting foot in unknown territory but, instead, saving cash for a rainy day.
Upvote Downvote

Accenture's (ACN) CEO Pierre Nanterme on Q1 2017 Results - Earnings Call Transcript

2016-12-21 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to Accenture's First Quarter Fiscal 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will be given at that time. [Operator Instructions] And as a reminder, this conference is being recorded.
Upvote Downvote

Accenture (ACN) Closes Acquisition of 47.4% Stake in OCTO

2016-11-28 zacks
Accenture Plc (ACN - Free Report) recently announced the completion of its pending acquisition of 47.4% stake in OCTO Technology. The global IT services provider had announced this acquisition in September this year. The move is believed to be a part of Accenture's efforts to enhance its digital marketing capabilities in France.
Upvote Downvote

Accenture Gets Help From Digital to Beat Revenue Estimate

2016-09-30 fortune
Consulting and outsourcing services provider Accenture reported better-than-expected quarterly revenue and profit as its investments to boost digital and cloud services pay off.
Upvote Downvote

Accenture (ACN) to Report Q4 Earnings: What's in the Cards?

2016-09-26 zacks
Accenture Plc (ACN - Analyst Report) is set to report fiscal fourth-quarter 2016 results on Sep 29, 2016. Last quarter, the company posted a positive earnings surprise of 0.71%. Let us see how things are shaping up for this announcement. Factors to Consider Accenture delivered better-than-expected third quarter fiscal 2016 results. Revenues increased on a year-over-year basis, reflecting increased focus on the Consulting and Outsourcing business, new bookings and continuous return of shareholders’ value.
Upvote Downvote

Accenture Buys Stake in OCTO, Boosts Digital Marketing

2016-09-19 zacks
Global IT services provider, Accenture plc (ACN - Analyst Report) recently announced a definitive agreement  to acquire a 47.4% stake in OCTO Technology. The move is part of Accenture's efforts to enhance its digital marketing capabilities in France.   OCTO Technology is a technology consultancy focusing on digital transformation and software development. The company employs more than 320 people in five countries namely France, Brazil, Switzerland, Morocco, and Australia.
Upvote Downvote

Deals of the day- Mergers and acquisitions

2016-09-15 reuters
Sept 15 The following bids, mergers, acquisitions and disposals were reported by 1020 GMT on Thursday:
Upvote Downvote

Paperboard firm Powerflute says to be bought for $354 mln

2016-09-15 reuters
HELSINKI Finnish paperboard company Powerflute Oyj (POWR.L) recommended cash offer from private equity firm Madison Dearborn Partners LLC for 268 million pounds ($354 million), it said on Thursday.
Upvote Downvote

UK's Informa to buy U.S.-based Penton for $1.56 billion

2016-09-15 reuters
British business information group Informa Plc (INF.L) said it had agreed to buy U.S.-based information services company Penton, from private equity firms MidOcean Partners and Wasserstein & Co for 1.18 billion pounds ($1.56 billion) to expand in the United States.
Upvote Downvote

Sonova still hunting retail, service targets in U.S., Australia

2016-09-15 reuters
ZURICH Sonova (SOON.S) Chief Executive Lukas Braunschweiler remains on the hunt for acquisitions to expand the Swiss hearing aid maker's retail and service presence in markets such as the United States and Australia, he told Reuters.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...